Pharmacotherapy of social anxiety disorder
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Social anxiety disorder (SAD) is one of the most common psychiatric disorders, with a lifetime prevalence of 5-12%. Fears of scrutiny and embarrassment in social and public situations are accompanied by anxiety symptoms, avoidance behavior, and impairment in social and work functioning. Several classes of medication, as well as cognitive-behavioral therapies, have evidence for efficacy in the treatment of SAD, but only a minority of individuals with the disorder receives treatment. AREAS COVERED: This review focuses on the evidence-based treatment of SAD with medications including serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, other antidepressants, benzodiazepines, alpha-delta calcium-channel agents, and beta-adrenergic blockers. It discusses clinical considerations in the selection and monitoring of treatments, including issues of safety, duration of treatment, comorbidity, and integration of medication with psychotherapeutic treatment. For this review, a PubMed literature search was conducted during July, 2010. EXPERT OPINION: Medications in several classes have been demonstrated efficacious in the treatment of SAD. Treatment selection and implementation require attention to clinical diagnosis, patient education, and appropriate monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
The etiology of social phobia: empirical evidence and an initial model
Rapee, R. M., & Spence, S. H. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.06.004 · Cited by 693
Grant, B. F., Hasin, D. S., Blanco, C., Stinson, F. S., Chou, S. P., Goldstein, R. B., Dawson, D. A., Smith, S., Saha, T. D., & Huang, B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1102 · Cited by 601 · cited 1×
“2 Epidemiology Epidemiological studies have reported lifetime prevalences of SAD to range from 5 to 12% in the United States; 1-year prevalence rates are 3 -- 7% [1,2].”
BackgroundCognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Self-citationClark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561 · cited 2×
“In a comparison of CBT to fluoxetine + self-exposure and placebo + self-exposure, after 16 weeks, there were significant improvements from all three treatments, but CBT was superior to both medication and placebo at post-treatment and 12-month follow-up, whereas fluoxetine did not differ from placebo [23].”
BackgroundAugmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 1×
“Patients who had received D-cycloserine showed significantly greater improvement on self-report measures than those who had received placebo, and this superior response was maintained 1 month after treatment had ended [77].”
BackgroundPhenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 2×
“The irreversible MAOI phenelzine, at doses of 30 -- 90 mg/day, has appeared effective for SAD in four controlled trials [35], and this efficacy was confirmed in a recent meta-analysis (n = 3 studies; RR = 2.”
BackgroundSelf-citationFluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415 · cited 1×
“Another study compared a different form of CBT to fluoxetine, placebo, and their combinations (CBT/fluoxetine and CBT/placebo) in a large, multisite sample of individuals with generalized SAD [73].”
BackgroundCognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404 · cited 2×
“Some other comparative studies have limited importance for understanding relative efficacy because they compared CBT to medications that were not themselves superior to placebo [48,56], or modified the CBT procedure such that its efficacy may have been reduced [45].”
BackgroundSocial Phobia Subtypes in the National Comorbidity Survey
Kessler, R. C., Stein, M. B., & Berglund, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.613 · Cited by 398 · cited 1×
“Persons with this generalized subtype have some clinical differences from persons with fear confined only to one or a few performance situations [8].”
BackgroundGuastella, A. J., Howard, A. L., Dadds, M. R., Mitchell, P., & Carson, D. S. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.01.005 · Cited by 366
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003) · Neurology · doi:10.1212/01.wnl.0000055434.39968.67 · Cited by 362 · cited 1×
“Notably, there have also been multiple case reports of the emergence of SAD symptoms during treatment of other disorders with antipsychotic medications [55].”
BackgroundBarriers to the Treatment of Social Anxiety
Olfson, M., Guardino, M., Struening, E., Schneier, F. R., Hellman, F., & Klein, D. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.521 · Cited by 356 · cited 1×
“Barriers to treatment that may be particularly common among those with SAD include uncertainty over where to go for help and fear of what others might think or say [5].”
BackgroundSelf-citationGuastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.011 · Cited by 326 · cited 1×
“These findings were replicated in a sample of 56 patients with SAD following a similar protocol [78].”
BackgroundEvaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder
ZAIDER, T. I., HEIMBERG, R. G., FRESCO, D. M., SCHNEIER, F. R., & LIEBOWITZ, M. R. (2003) · Psychological Medicine · doi:10.1017/s0033291703007414 · Cited by 286
Self-citationAnxiety disorders and suicidality in the National Comorbidity Survey-Replication
Cougle, J. R., Keough, M. E., Riccardi, C. J., & Sachs-Ericsson, N. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.12.004 · Cited by 253 · cited 1×
“Persons with SAD tend to have fewer social supports than desired, are less likely to marry, show impairment in school and work functioning, and have increased suicide attempts [3,4].”
BackgroundPande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227 · cited 2×
“In the olanzapine study [51], the response rates for medication and placebo (43 vs 0%, respectively) did not differ significantly, but the olanzapine-treated patients had significantly superior outcomes in social-anxiety-specific scales.”
BackgroundResultAttentional focus in social anxiety disorder: Potential for interactive processes
Schultz, L. T., & Heimberg, R. G. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2008.04.003 · Cited by 212 · cited 1×
“In addition to the prototypical features of excessive fear of embarrassment and associated social avoidance, other common features of SAD include physical symptoms of blushing, sweating or trembling [6], and associated cognitive processes of selfdirected attention and fears of negative evaluation [7].”
BackgroundBlanco, C., Heimberg, R. G., Schneier, F. R., Fresco, D. M., Chen, H., Turk, C. L., Vermes, D., Erwin, B. A., Schmidt, A. B., Juster, H. R., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.11 · Cited by 206 · cited 1×
“A subsequent study at the same sites compared the combination of CBT + phenelzine to monotherapy with CBT, phenelzine, or placebo in 128 patients with SAD [72].”
ResultSelf-citationAdler, L. A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009) · Depression and Anxiety · doi:10.1002/da.20549 · Cited by 176 · cited 1×
“A large multicenter RCT in adults with SAD comorbid with attention-deficit/hyperactivity disorder (ADHD) found that atomoxetine monotherapy improved both ADHD and SAD symptoms more than placebo [67].”
BackgroundOtto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G. (2000) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(00)00027-x · Cited by 175 · cited 1×
“Clonazepam efficacy for SAD is further supported by findings from several open trials and a controlled comparison in which it was superior to CBT on several measures [44].”
ResultLader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163 · cited 1×
“The few existing fixed-dose studies have failed to show consistent dose--response effects, including findings that venlafaxine extended release was no less effective at a dose of 75 mg/day (believed to specifically result in blockade of serotonin but not norepinephrine reuptake), than in higher doses that are thought…”
BackgroundElevated Fear Conditioning to Socially Relevant Unconditioned Stimuli in Social Anxiety Disorder
Lissek, S., Levenson, J., Biggs, A. L., Johnson, L. L., Ameli, R., Pine, D. S., & Grillon, C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06091513 · Cited by 158
Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial
Haug, T. T., Blomhoff, S., Hellstrøm, K., Holme, I., Humble, M., Madsbu, H. P., & Wold, J. E. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.4.312 · Cited by 151 · cited 1×
“At 1-year follow-up, however, patients in the sertraline-only and combined sertraline + exposure groups demonstrated greater deterioration than the exposure-only group [75].”
BackgroundMontgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115 · cited 1×
“2 SSRIs and SNRIs: long-term treatment/ discontinuation Three studies have randomized patients who had responded to an acute 12- to 20-week trial of SSRI or SNRI to either continuation of active treatment or double-blind switch to placebo [32-34].”
BackgroundCornwell, B. R., Johnson, L., Berardi, L., & Grillon, C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.015 · Cited by 103 · cited 1×
“There is evidence for dysregulation of serotonin, dopamine, glutamate, and hypothalamic--pituitary--adrenal axis systems [13], as well as differences in startle and autonomic reactivity [14].”
BackgroundWalker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84 · cited 1×
“2 SSRIs and SNRIs: long-term treatment/ discontinuation Three studies have randomized patients who had responded to an acute 12- to 20-week trial of SSRI or SNRI to either continuation of active treatment or double-blind switch to placebo [32-34].”
Background
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Behl, T., Kaur, D., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Andronie-Cioara, F. L., Toma, M. M., Bungau, S., & Bumbu, A. G. (2021) · Molecules · doi:10.3390/molecules26123724 · Cited by 317
Should OCD be classified as an anxiety disorder in DSM-V?
Stein, D. J., Fineberg, N. A., Bienvenu, O. J., Denys, D., Lochner, C., Nestadt, G., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2010) · Depression and Anxiety · doi:10.1002/da.20699 · Cited by 212
SOCIAL ANXIETY DISORDER IN DSM-5: Review: Social Anxiety Disorder in DSM-5
Heimberg, R. G., Hofmann, S. G., Liebowitz, M. R., Schneier, F. R., Smits, J. A. J., Stein, M. B., Hinton, D. E., & Craske, M. G. (2014) · Depression and Anxiety · doi:10.1002/da.22231 · Cited by 166
Self-citationAlkhalifa, A. E., Alkhalifa, O., Durdanovic, I., Ibrahim, D. R., & Maragkou, S. (2025) · Journal of Dementia and Alzheimer's Disease · doi:10.3390/jdad2020017 · Cited by 66
Metadata
- Authors
- Schneier, F. R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-01-18
- Volume
- 12
- Issue
- 4
- Pages
- 615-625
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2075736632
- Cited by
- 41
- References
- 28
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.